Verrica Pharmaceuticals is a skin disease-focused pharmaceutical company that develops and sells treatments for dermatologic conditions in the United States. The company markets YCANTH, a combination drug-device product containing cantharidin to treat molluscum and common warts in both children and adults, and is testing VP-315, a peptide-based injectable therapy currently in phase II trials for skin cancers such as basal cell carcinoma. The company has partnerships with Torii Pharmaceutical for distribution in Japan and with Lytix Biopharma to develop VP-315 for malignant and pre-malignant skin conditions.

entry readiness 75 · GOOD SETUP · exit proximity 0

Value area 4.81–6.49 · 98% of 120d volume overhead · heavy supply